UBS Group’s Innovator IBD ETF Leaders ETF LDRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-830
| Closed | -$23K | – | 10735 |
|
|
2021
Q2 | $23K | Sell |
830
-1,672
| -67% | -$46K | ﹤0.01% | 7219 |
|
|
2021
Q1 | $67K | Buy |
2,502
+2,146
| +603% | +$61.4K | ﹤0.01% | 6271 |
|
|
2020
Q4 | $10K | Sell |
356
-2,031
| -85% | -$54.4K | ﹤0.01% | 7533 |
|
|
2020
Q3 | $58K | Sell |
2,387
-747
| -24% | -$17.4K | ﹤0.01% | 5547 |
|
|
2020
Q2 | $64K | Sell |
3,134
-3
| -0.1% | -$57 | ﹤0.01% | 5670 |
|
|
2020
Q1 | $58K | Buy |
3,137
+1,623
| +107% | +$34.7K | ﹤0.01% | 5714 |
|
|
2019
Q4 | $34K | Sell |
1,514
-500
| -25% | -$11.1K | ﹤0.01% | 6578 |
|
|
2019
Q3 | $44K | Buy |
2,014
+479
| +31% | +$10.5K | ﹤0.01% | 6273 |
|
|
2019
Q2 | $33K | Sell |
1,535
-1,331
| -46% | -$28.1K | ﹤0.01% | 6273 |
|
|
2019
Q1 | $61K | Buy |
2,866
+379
| +15% | +$8.11K | ﹤0.01% | 5416 |
|
|
2018
Q4 | $53K | Buy |
2,487
+375
| +18% | +$8.57K | ﹤0.01% | 6048 |
|
|
2018
Q3 | $54K | Buy |
2,112
+2,109
| +70,300% | +$53.6K | ﹤0.01% | 6109 |
|
|
2018
Q2 | $0 | Sell |
3
-1,952
| -100% | -$48.3K | ﹤0.01% | 8379 |
|
|
2018
Q1 | $48K | Buy |
+1,955
| New | +$50.2K | ﹤0.01% | 5747 |
|
UBS Group's LDRS Position: Q3 2021 in Review
UBS Group sold out of Innovator IBD ETF Leaders ETF (LDRS) in Q3 2021, closing a stake of 830 shares — an estimated $23K sold.
UBS Group first reported a position in LDRS in Q1 2018 and held it in 14 quarters. The position peaked at $67K in Q1 2021. 0 funds tracked by Wall St. Rank hold LDRS as of Q3 2021.
- UBS Group reported no remaining Innovator IBD ETF Leaders ETF position as of Q3 2021 after selling out during the quarter.
- UBS Group sold 830 Innovator IBD ETF Leaders ETF shares in Q3 2021, an estimated $23K.
- UBS Group first reported a position in Innovator IBD ETF Leaders ETF in Q1 2018 and held it in 14 quarters.
- UBS Group's Innovator IBD ETF Leaders ETF position peaked at $67K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Innovator IBD ETF Leaders ETF as of Q3 2021.
Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.